Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 256 followers
Latest posts
Last updated about 19 hours ago
R3 Vascular raises $87M to test its bioresorbable scaffold for blocked arteries below the knee
about 21 hours ago
R3 Vascular raises $87M to test its bioresorbable scaffold for blocked arteries...
Bayer lifts lid on pivotal data ahead of filings to challenge Astellas for menopause market
1 day ago
Bayer lifts lid on pivotal data ahead of filings to challenge Astellas...
Erasca lays off 18% while swapping out KRAS program for fresh anti-tumor options
1 day ago
Erasca lays off 18% while swapping out KRAS program for fresh anti-tumor...
Very rare COVID vaccine-related blood clots share genes with condition linked to common cold
1 day ago
Very rare COVID vaccine-related blood clots share genes with condition linked to...
Chutes & Ladders—Atai appoints co-CEO and a Fierce goodbye
1 day ago
Chutes & Ladders—Atai appoints co-CEO and a Fierce goodbye gmasson Thu, 05/16/2024...
Going beyond A, B & O: Thermo Fisher unveils DNA test for the rarest blood types
2 days ago
Going beyond A, B & O: Thermo Fisher unveils DNA test for...
PCOS infertility treatment developer May Health raises $25M
2 days ago
PCOS infertility treatment developer May Health raises $25M chale Thu, 05/16/2024 -...
J&J hooks Proteologix for $850M cash, reeling in a roster of early bispecifics
2 days ago
J&J hooks Proteologix for $850M cash, reeling in a roster of early...
Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data
2 days ago
Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical...
AstraZeneca prepares fresh COVID push to regulators after antibody’s phase 3 success
2 days ago
AstraZeneca prepares fresh COVID push to regulators after antibody’s phase 3 success...
Lilly keeps on Novo's tail by reporting weekly insulin hits primary endpoint in 2 pivotal trials
2 days ago
Lilly keeps on Novo's tail by reporting weekly insulin hits primary endpoint...
Roche’s $2.7B Carmot bet pays off with phase 1 weight loss success for GLP-1/GIP agonist
2 days ago
Roche’s $2.7B Carmot bet pays off with phase 1 weight loss success...